Annuncio • Mar 31
Aptamer Group PLC has completed a Follow-on Equity Offering in the amount of £0.273993 million. Aptamer Group PLC has completed a Follow-on Equity Offering in the amount of £0.273993 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 45,665,573
Price\Range: £0.006
Security Features: Attached Warrants
Transaction Features: Regulation S Reported Earnings • Mar 30
First half 2026 earnings released: EPS: UK£0 (vs UK£0.001 loss in 1H 2025) First half 2026 results: EPS: UK£0. Revenue: UK£828.0k (up 27% from 1H 2025). Net loss: UK£1.15m (loss widened 3.2% from 1H 2025). Annuncio • Mar 25
Aptamer Group PLC has filed a Follow-on Equity Offering in the amount of £3.75 million. Aptamer Group PLC has filed a Follow-on Equity Offering in the amount of £3.75 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 625,000,000
Price\Range: £0.006
Security Features: Attached Warrants
Transaction Features: Regulation S Reported Earnings • Dec 21
Full year 2025 earnings released: UK£0.001 loss per share (vs UK£0.007 loss in FY 2024) Full year 2025 results: UK£0.001 loss per share (improved from UK£0.007 loss in FY 2024). Revenue: UK£1.20m (up 40% from FY 2024). Net loss: UK£2.42m (loss narrowed 18% from FY 2024). Annuncio • Nov 04
Aptamer Group PLC, Annual General Meeting, Nov 27, 2025 Aptamer Group PLC, Annual General Meeting, Nov 27, 2025. Location: windmill house, innovation way, york, yo10 5br, United Kingdom Reported Earnings • Oct 14
Full year 2025 earnings released: UK£0.001 loss per share (vs UK£0.007 loss in FY 2024) Full year 2025 results: UK£0.001 loss per share (improved from UK£0.007 loss in FY 2024). Revenue: UK£1.20m (up 40% from FY 2024). Net loss: UK£2.42m (loss narrowed 18% from FY 2024). Annuncio • Oct 14
Aptamer Group plc Provides Earnings Guidance for the Year to 30 June 2026 Aptamer Group PLC provided earnings guidance for the year to 30 June 2026. For the year, the company anticipated to be higher than was the case in the year to June 2025. Within this forecast, delivery of full year revenue expectations would ensure that the resultant positive cashflows together with the current cash balance are sufficient to see the Group through to 30 June 2027. Annuncio • Oct 10
Aptamer Group PLC to Report Fiscal Year 2025 Results on Oct 14, 2025 Aptamer Group PLC announced that they will report fiscal year 2025 results on Oct 14, 2025 New Risk • Sep 28
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 22% per year over the past 5 years. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Revenue is less than US$5m (UK£1.2m revenue, or US$1.6m). Market cap is less than US$100m (UK£20.9m market cap, or US$28.0m). Annuncio • Aug 29
Aptamer Group plc Announces the Launch of Its Biomarker Discovery Service Aptamer Group plc announced the launch of its biomarker discovery service, creating a new fee-for-service revenue stream targeting the USD 62.4 billion global biomarker discovery market. Biomarkers are essential molecular indicators of physiological states, including disease presence and progression, and play a critical role in enabling targeted drug development, early diagnosis, treatment monitoring and safety assessment. The identification of new biomarkers is a key driver of innovation in healthcare, particularly in areas of high unmet medical need where the absence of suitable biomarkers has historically limited therapeutic and diagnostic advancement. Aptamer's biomarker discovery service represents a transformative shift from traditional, time-intensive methods by harnessing its proprietary Optimer technology in combination with advanced proteomic analysis, the large-scale study of proteins in a biological system. This approach enables rapid, unbiased identification of disease-specific biomarkers by differentiating healthy and diseased cell states at the molecular level. Crucially, it not only identifies validated biomarkers but also simultaneously generates high-affinity binding molecules that are ready for immediate integration into commercial applications. This dual-output capability significantly accelerates development timelines for pharmaceutical research, biotechnology innovation and diagnostic test creation, offering a powerful solution for companies seeking to advance targeted therapies and enable earlier, more accurate disease detection. Delivered under Aptamer's established fee-for-service model, the new biomarker discovery offering provides an immediate monetisation opportunity for the Company with minimal upfront investment and is expected to be revenue enhancing in the current financial year. Operating within a large and growing market driven by the rise of precision medicine, the service is well-positioned to capture significant demand from pharmaceutical, biotech and diagnostic developers. Early interest has already been demonstrated following the successful internal application of the platform to identify the biomarker targeted by Aptamer's fibrotic liver delivery system - highlighting its potential to deliver faster, actionable insights and validating its commercial relevance. Launching on a fee-for-service basis, the service enables pharmaceutical and biotechnology partners to accelerate R&D pipelines without significant capital expenditure, supporting Aptamer's revenue diversification strategy. Annuncio • Aug 22
Aptamer Group plc Provides an Update on Its Enrollment Modulating Optimer Projects and A Separate Development Project with A Top Five Pharmaceutical Company Aptamer Group plc provided an update on its enzyme modulation projects and a separate development project with a top five pharmaceutical company, highlighting significant advancements in licensing and development. First enzyme-modulating Optimer-modulating Optimer - multiple non-exclusive licensing opportunities Aptamer's Optimer binders modulate enzyme activity by specifically binding to the enzyme, changing its shape or blocking its active site, which can either inhibit or activate its function. This is commercially important because they enable precise, tunable control of enzyme activity, unlocking new possibilities for targeted therapeutics, diagnostics, molecular tools and industrial bioprocessing. The following license opportunities are related to exploitation in diagnostics and molecular tool applications. Licence 1: Aptamer has received initial sales forecasts from its first partner for the first commercial enzyme inhibitor in one specific application area. This 10-year non-exclusive licensing deal, which is at an advanced stage of negotiation, is forecast to cover approximately 15% of the Group's annual overhead through passive income over the next three years. This forecast is subject to the partner achieving its projected sales targets, with commercial sales anticipated to begin before the end of the year. Licence 2: Aptamer continues to advance licensing discussions with a second partner, a growing global distributor of enzymes for non-exclusive access to this enzyme-modulating product. Sales forecasts are currently being finalised for this second licensing agreement. Updates will be provided as discussions progress. Licence 3: Aptamer has further signed a Material Transfer Agreement (MTA) with a third partner, a leading global distributor of enzymes, to allow this partner to evaluate the technology. This agreement positions the Company for a potential third non-exclusive licence in this area, further demonstrating the growing interest in Optimer binders for enzyme modulation applications and demand for new solutions in this field. Second enzyme-modulating Optimer project - final development stage Following successful completion and customer approval of all earlier phases, Aptamer has advanced its second enzyme inhibitor project to the final development stage. Discussions are underway regarding a second licensing deal for this reagent, expanding Aptamer's portfolio to include two separate enzyme modulation technologies based on its proprietary Optimer platform. Separate from the announcement on 18 August 2025, Aptamer has received extremely positive feedback from a top five global pharmaceutical partner on their evaluation of the Optimer®?. The customer has evaluated the Optimer®? in a parallel application, showing that the Optimer®? significantly outperformed all previously tested antibodies. As a result, the customer has placed repeat orders of the Optimer®? to expand internal testing and evaluation of the technology. The developed Optimer®? will be used to support a current clinical drug development programme, with licensing agreements for such reagents typically commanding up to hundreds of thousands of pounds. These developments underscore the commercial potential of Aptamer's Optimer®? technology in providing innovative antibody-alternative solutions, with opportunities for recurring revenue through licensing and royalties. New Risk • Aug 04
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 22% per year over the past 5 years. Shareholders have been substantially diluted in the past year (469% increase in shares outstanding). Minor Risks Revenue is less than US$5m (UK£1.2m revenue, or US$1.6m). Market cap is less than US$100m (UK£12.2m market cap, or US$16.3m). Annuncio • May 07
Aptamer Group plc Announces the Successful Adaptation of the Optimer-Based Test for Alzheimer's Disease into an Enzy Me-Linked Immunosorbent Assay Aptamer Group plc announced the successful adaptation of the Optimer-based test for Alzheimer's disease into an Enzy me-Linked Immunosorbent Assay (ELISA), a format widely accepted and used in hospital laboratories. Aptamer has also finalised a royalty agreement with its development partner, Neuro-Bio Ltd. Under the agreed terms, Aptamer is eligible to receive royalty payments with a blended royalty rate of 11.1% on the first PS166 million of sales, with 5% thereafter for a 15-year term starting at first commercial sales across this diagnostic format. The partners estimate developing and validating a prototype ELISA assay over the next 12-18 months for transfer to a manufacturer or distributor. This advance in test development follows the recent demonstration of an Optimer-based biosensor test that showed a statistically significant difference in levels of a novel Alzheimer's disease biomarker between saliva samples from Alzheimer's patients and healthy patient controls. Initial in-house validation of the plate-based ELISA assay at Aptamer has shown accurate detection of the biomarker over a clinically relevant range and compatibility with saliva for convenient patient sampling. Further development efforts are being made to clinically validate the new test format. To capitalise on the potential of this patient-friendly test for Alzheimer's disease that uses saliva sampling, a staged diagnostic development strategy is now underway with Neuro-Bio, which aims to maximise market access with an initial focus on advancing the ELISA assay for widespread clinical adoption. The Alzheimer's disease diagnostic market is valued at $8.3 billion, limited by the availability of any definitive diagnostic tests, and is expected to rise to $19.6 billion by 2029. While several Alzheimer's diagnostics are in development, the test being developed by Aptamer and Neuro-Bio leverages non-invasive saliva sampling, offering a rapid, convenient and patient-friendly approach with the potential to transform the diagnostic market for this disease by increasing accessibility and accelerating time-to-diagnosis. Annuncio • Apr 29
Aptamer Group plc to Present New Data on Optimer Delivery Vehicle Targeting Fibrotic Liver Aptamer Group plc announced that it will present new data showcasing its proprietary Optimer delivery vehicle targeting fibrotic liver at the upcoming 2025 American Society for Gene and Cell Therapy (ASGCT) Annual Meeting, to be held from 13 - 17 May 2025 in New Orleans, Louisiana. Dr David Bunka, Aptamer's Chief Scientific Officer, will present the latest advances regarding Aptamer's proprietary Optimer delivery vehicle, demonstrating its precision-targeting capabilities for fibrotic liver disease - a major unmet clinical need with significant commercial potential. The new data will show how the Optimer delivery vehicle enables targeted delivery of RNAi therapies specifically to activated hepatic stellate cells, the key drivers of liver fibrosis. Current gene therapies face well-documented barriers in achieving cell-specific targeting, intracellular uptake, and endosomal escape. Optimer delivery vehicles are designed to overcome each of these challenges, unlocking new possibilities for effective, tissue-specific gene therapies across a wide range of chronic diseases. This targeted delivery technology has the potential to enhance therapeutic efficacy, reduce off-target effects, and broaden the clinical utility of gene therapies, addressing a critical barrier in RNAi drug development. Reported Earnings • Mar 16
First half 2025 earnings released: UK£0.001 loss per share (vs UK£0.005 loss in 1H 2024) First half 2025 results: UK£0.001 loss per share (improved from UK£0.005 loss in 1H 2024). Revenue: UK£653.0k (up 119% from 1H 2024). Net loss: UK£1.11m (loss narrowed 39% from 1H 2024). New Risk • Mar 11
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£1.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Earnings have declined by 22% per year over the past 5 years. Shareholders have been substantially diluted in the past year (311% increase in shares outstanding). Market cap is less than US$10m (UK£6.34m market cap, or US$8.21m). Minor Risks Share price has been volatile over the past 3 months (9.5% average weekly change). Revenue is less than US$5m (UK£1.2m revenue, or US$1.6m). Annuncio • Feb 25
Aptamer Group PLC to Report First Half, 2025 Results on Mar 11, 2025 Aptamer Group PLC announced that they will report first half, 2025 results on Mar 11, 2025 Recent Insider Transactions • Dec 11
Key Executive recently bought UK£61k worth of stock On the 9th of December, Adam Hargreaves bought around 20m shares on-market at roughly UK£0.0031 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Adam's only on-market trade for the last 12 months. New Risk • Dec 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 36% per year over the past 5 years. Shareholders have been substantially diluted in the past year (311% increase in shares outstanding). Market cap is less than US$10m (UK£6.91m market cap, or US$8.84m). Minor Risk Revenue is less than US$5m (UK£860k revenue, or US$1.1m). Annuncio • Dec 06
Aptamer Group PLC Announces Three New Members to its Scientific Advisory Board Aptamer Group PLC announced three new members to its Scientific Advisory Board (SAB). Dr Paloma Giangrande, Dr Louis Allot, and Dr Adam Hargreaves join Aptamer's SAB with established members Professor Paul Townsend and Dr Shozo Fujita. The team will provide scientific expertise, an extensive contact network, and valuable market insights. The newly formed SAB will primarily be focused on addressing the commercialisation of the Group's internal development programmes for targeted delivery vehicles with diverse payloads, such as siRNA therapies and radiopharmaceuticals. The collaborative possibilities for advancing Optimer binders across multiple application areas are strengthened by the addition of industry experts to Aptamer's SAB, who will review and advise on product strategies, scientific approaches, and evidence generation for data to enable clinical advancement. The SAB is chaired by Dr David Bunka, Aptamer's Chief Scientific Officer and deputy chaired by Dr Arron Tolley, Aptamer's Chief Executive Officer. The SAB now comprises the following highly qualified industry experts: Dr. Adam Hargreaves, Managing Director of Pathcelerate and Aptamer Chair; Dr. Paloma Giangrande, former CTO at Eleven Therapeutics and Editor-in-Chief at Molecular Therapy Nucleic Acids; Dr. Louis Allot, Radiochemistry Consultant at Radiopharmium; Professor Paul Townsend, Deputy Principal of Research and Innovation at the University of Stirling; Dr. Shozo Fujita, Former Chief Technology Officer at Apta-Bio. Dr. Paloma Giangrande is an internationally recognised expert in the development and translation of nucleic acid therapeutics and aptamer-based delivery. She pioneered the use of RNA aptamers for targeted siRNA delivery beyond the liver, significantly expanding the therapeutic potential of RNA interference. Paloma has held key leadership roles in renowned biotechnology companies, including Moderna, Wave Life Sciences, and Eleven Therapeutics. Her strategic leadership at prestigious institutions underscores her commitment to advancing innovative RNA-based treatments. Dr Louis Allot is an expert in the clinical development of radiopharmaceuticals. He has extensive experience in developing novel radiopharmaceutical technologies from small molecules, to proteins, aptamers and antibodies. He has previously held positions at Imperial College London, the University of Hull, and the Molecular Imaging Research Centre (MIRC), a state-of-the-art GMP radiopharmaceutical production facility. Louis holds an honorary position as Lecturer in Radiochemistry at King's College London and, through Radiopharmium continues to be actively involved in translational research concerning the targeted delivery of radiopharmaceuticals. Dr Adam Hargreaves is the founder of PathCelerate Limited. Spanning a 20-year career, he has previously worked for AstraZeneca and has expertise in preclinical and translational small molecule, biologic, and RNA-based pharmaceuticals. Adam is a Fellow of the Royal College of Pathologists and is a board-certified Diplomate of the American College of Veterinary Pathology. Adam joined Aptamer Group as a Non-Executive Director in 2023 and moved to Non-Executive Chair in 2024. Annuncio • Nov 06
Aptamer Group plc, Annual General Meeting, Nov 29, 2024 Aptamer Group plc, Annual General Meeting, Nov 29, 2024. Location: the offices of aptamer group, windmill house, innovation way, heslington, yo10 5br, york United Kingdom Reported Earnings • Oct 23
Full year 2024 earnings released: EPS: UK£0.007 (vs UK£0.11 loss in FY 2023) Full year 2024 results: EPS: UK£0.007 (up from UK£0.11 loss in FY 2023). Revenue: UK£860.0k (down 51% from FY 2023). Net loss: UK£2.96m (loss narrowed 62% from FY 2023). Annuncio • Oct 17
Aptamer Group plc to Report Fiscal Year 2024 Results on Oct 22, 2024 Aptamer Group plc announced that they will report fiscal year 2024 results on Oct 22, 2024 New Risk • Oct 14
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 44% per year over the past 5 years. Shareholders have been substantially diluted in the past year (311% increase in shares outstanding). Market cap is less than US$10m (UK£4.13m market cap, or US$5.39m). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Revenue is less than US$5m (UK£1.0m revenue, or US$1.4m). Board Change • Sep 22
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 4 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Chief Scientific Officer, Member of the Scientific Advisory Board & Executive Director David Bunka is the most experienced director on the board, commencing their role in 2014. Independent Non-Executive Director Dean Fielding was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Annuncio • Sep 16
Aptamer Group plc Announces Appointment of Tim Sykes to Its Board of Directors Aptamer Group plc announced the appointment of Tim Sykes to its Board of Directors as a Non-Executive Director with immediate effect. Tim is an experienced executive and non-executive director, having been CEO and, previously, CFO of Proactis Holdings PLC between 2006 and 2022 and having served as fractional or transitionary CFO at Avacta Group plc, Altitude Group, and Eleco plc. Tim currently serves as Non-Executive Director at Data Connect Group Limited and as fractional CFO at Rio AI Limited. Tim is a qualified chartered accountant, and at Aptamer Group he is Chair of the Audit Committee and a member of the Remuneration Committee. Current directorships: Data Connect Group Limited; Mooring Management (Filey) Limited. Former appointments within the past 5 years: Proactis Holdings PLC. In 2018, Mr. Sykes was a director of Penta Financial Direction Limited when it was liquidated with no loss to creditors. In 2017, Mr. Sykes was a director of Proactis Total Procure Limited, which was a Proactis joint venture in India, when it was compulsorily struck off having ceased to trade. Annuncio • Aug 13
Aptamer Group plc Announces Board Changes Aptamer Group announced that, further to the Company's announcement on 24 July 2024 and subsequent announcement on 1 August 2024, at its General Meeting held on August 13, 2024, all Resolutions were passed. Accordingly, all of the proposals set out in the Company's circular dated 24 July 2024 (the "Circular") and the announcement made on 1 August 2024 will proceed. With effect from Admission (scheduled for 8:00 a.m. on 14 August 2024), the board will comprise: Dr. Adam Hargreaves (Non-Executive Chairman), Dr. Arron Tolley (Chief Executive Officer), Dr. David Bunka (Chief Scientific Officer), and Andrew Rapson (Chief Financial Officer). The resignations of Stephen Hull (Executive Chairman) and Dean Fielding (Non-Executive Director) take effect from Admission. The Company is still to looking to appoint another Non-Executive Director at the earliest opportunity. Annuncio • Mar 22
Aptamer Group plc to Report First Half, 2024 Results on Mar 28, 2024 Aptamer Group plc announced that they will report first half, 2024 results on Mar 28, 2024 Annuncio • Feb 27
Aptamer Group plc Announces R&D Progress on New Optimer®? + Platform Aptamer Group plc announced an update on the technical progress made with the new Optimer®? + programme. Optimer®? + is a novel affinity ligand platform that can be considered amongst the next generation of binding reagents, beyond current Optimer®?-based offering. Since last year's fundraising activities, the Company has focused on advancing the Optimer®? + programme as one of the key strands of its new strategy. The Company is now pleased to report that excellent progress has been made in developing the new platform. Current data shows that Optimer®? + binders can be isolated against a range of target types, including those with high therapeutic value. This means that the platform is applicable throughout the life sciences industry, in several settings, including the development of disease-modifying biopharmaceuticals; radionucleotide and gene therapy delivery; and the targeting of infectious disease. The latest proof-of-concept results show that the Optimer®? + platform can produce highly specific binders with significantly higher affinity than the current technology platform. Development times for Optimer®? + are also significantly faster than existing aptamer-based approaches. Lab-based results have shown Optimer®? + binder in blood serum and are not harmful to cells. Furthermore, preliminary experiments in mice have shown Optimer®?+ binders to be well tolerated demonstrating the basic requirements for therapeutic applications. Optimer®?+ uses a modified oligonucleotide library that creates hybrid Optimer®? -peptide binders engineered with a scaffold structure that bridge the gap between traditional aptamers and protein-based affinity ligands. The Company's new platform combines the flexibility, manufacturing, and stability benefits of its current technology with the functional diversity and binding capability of a protein. This approach aligns the Optimer®? + platforms with high growth antibody alternatives such as Bicycles and DARPins. Aptamer expects the new Optimer®?+ platform to expand the capability of its binders in all applications, especially in precision medicine. The technology is fully protected with a portfolio of granted patents, ensuring Aptamer Group retains exclusive rights for all uses of the new system. Evaluation processes are ongoing within the Company and with external partners to optimise the development and large-scale manufacturing protocols, with an active marketing strategy to follow. New Risk • Feb 15
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£6.1m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 47% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (UK£2.69m market cap, or US$3.38m). Minor Risk Revenue is less than US$5m (UK£1.8m revenue, or US$2.2m). Annuncio • Feb 05
Aptamer Group plc Provides Revenue Guidance for the First Half of the Fiscal Year 2024 Aptamer Group plc provided revenue guidance for the first half of the fiscal year 2024. For the period, the company expects revenue to come in at approximately £0.3 million (first half fiscal year 2023: £1.0 million). Reported Earnings • Nov 24
Full year 2023 earnings released: UK£0.11 loss per share (vs UK£0.032 loss in FY 2022) Full year 2023 results: UK£0.11 loss per share (further deteriorated from UK£0.032 loss in FY 2022). Revenue: UK£1.75m (down 57% from FY 2022). Net loss: UK£7.84m (loss widened 274% from FY 2022). Annuncio • Nov 20
Aptamer Group plc, Annual General Meeting, Dec 15, 2023 Aptamer Group plc, Annual General Meeting, Dec 15, 2023, at 10:00 Coordinated Universal Time. Location: Windmill House, Innovation Way, York United Kingdom Annuncio • Nov 09
Aptamer Group plc to Report Fiscal Year 2023 Results on Nov 09, 2023 Aptamer Group plc announced that they will report fiscal year 2023 results on Nov 09, 2023 New Risk • Oct 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Earnings have declined by 39% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (UK£6.54m market cap, or US$7.98m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (UK£3.7m revenue, or US$4.5m). Annuncio • Sep 21
Aptamer Group plc has completed a Follow-on Equity Offering in the amount of £0.310772 million. Aptamer Group plc has completed a Follow-on Equity Offering in the amount of £0.310772 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 28,251,956
Price\Range: £0.011
Transaction Features: Subsequent Direct Listing New Risk • Aug 25
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 5x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£7.4m free cash flow). Share price has been highly volatile over the past 3 months (39% average weekly change). Earnings have declined by 39% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (UK£5.38m market cap, or US$6.76m). Minor Risk Revenue is less than US$5m (UK£3.7m revenue, or US$4.6m). Annuncio • Jun 14
Aptamer Group plc Announces Success in the Development of Optimer Binders to Enable A Lateral Flow Test for the Early Diagnosis of Alzheimer's Disease Aptamer Group plc announced success in the development of Optimer binders to enable a lateral flow test for the early diagnosis of Alzheimer's disease. Aptamer Group has successfully developed a panel of Optimer binders to a novel Alzheimer's disease biomarker. The Optimer binders have been patented by partners at Neuro-Bio, following the demonstration of performance in specifically binding to the target biomarker and functionality in a nasal mucous matrix. Further integration of the binders into a routine lateral flow test will support the clinical and commercial development of rapid diagnostics for Alzheimer's disease via simple nasal sampling, with the potential to diagnose the disease as early as 10-20 years before symptoms emerge. The novel Alzheimer's disease biomarker, a peptide 'T14'was discovered and is currently being further validated by Neuro-Bio, led by the eminent neuroscientist Baroness Susan Greenfield. Early detection of Alzheimer's disease is critical to allow interventions that could prevent the onset of devastating memory loss and confusion in these patients. Neuro-Bio is working in parallel to develop a complementary therapy that could stabilise disease progression in diagnosed patients, ideally at the presymptomatic stage. Annuncio • May 05
Aptamer Group plc Provides Revenue Guidance for the Year Ending 30 June 2023 Aptamer Group plc provided revenue guidance for the year ending 30 June 2023. For the year, the group now expects full year revenues to be materially below Full Year 2022. The sales pipeline remains healthy across both fee-for-service and licensing,and while the Group expects some of this to be recognised as revenue in the current financial year, the majority, if converted, will fall into the next financial year. Reported Earnings • Mar 16
First half 2023 earnings released: UK£0.038 loss per share (vs UK£0.018 loss in 1H 2022) First half 2023 results: UK£0.038 loss per share (further deteriorated from UK£0.018 loss in 1H 2022). Revenue: UK£1.02m (down 26% from 1H 2022). Net loss: UK£2.63m (loss widened 139% from 1H 2022). Revenue is forecast to grow 61% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Annuncio • Jan 11
Aptamer Group plc Appoints Derek Smith as Interim Chief Commercial Officer Aptamer Group plc announced the appointment of Derek Smith as interim chief commercial officer, effective as of 1 January 2023. Derek joined the company in 2018 as Director of Global Sales and has since become a vital part of the Aptamer team, overseeing the development and implementation of the Company’s global sales strategy and securing contracts across all three business divisions, including with a number of major pharmaceutical companies. Prior to joining Aptamer Group, Derek held senior sales positions at various UK healthcare companies. Annuncio • Jan 04
Aptamer Group plc Provides Revenue Guidance for the First Half and Full Year of 2023 Aptamer Group plc provided revenue guidance for the first half and full year of 2023. For the first half, the company expects revenues in the region of £1.0 million.For the year, revenue may fall below market expectations, but materially ahead of the level achieved last financial year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Senior Independent Director Angela Hildreth was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Annuncio • Dec 23
Aptamer Group plc has completed an IPO in the amount of £10.76645 million. Aptamer Group plc has completed an IPO in the amount of £10.76645 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 9,202,094
Price\Range: £1.17
Transaction Features: Regulation S